Atacicept

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Monthly Dosing of Atacicept in IgAN	2025/06/13	NCT07020923	Phase 2	Recruiting	Vera Therapeutics, Inc.
Atacicept in Multiple Glomerular Diseases	2025/05/21	NCT06983028	Phase 2	Not yet recruiting	Vera Therapeutics, Inc.
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept	2024/11/05	NCT06674577	Phase 2	ENROLLING_BY_INVITATION	Vera Therapeutics, Inc.
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)	2022/11/08	NCT05609812	Phase 3	Withdrawn	Vera Therapeutics, Inc.
Atacicept in Subjects With IgA Nephropathy	2021/01/20	NCT04716231	Phase 3	Active, not recruiting	Vera Therapeutics, Inc.
Efficacy and Safety of Atacicept in IgA Nephropathy	2016/06/21	NCT02808429	Phase 2	Terminated	EMD Serono Research & Development Institute, Inc.
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)	2014/02/25	NCT02070978	Phase 2	Terminated	EMD Serono
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus	2013/10/30	NCT01972568	Phase 2	Completed	EMD Serono
Atacicept Demonstrating Dose RESponSe	2011/09/26	NCT01440231	Phase 2	Withdrawn	EMD Serono
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil	2011/06/09	NCT01369628	Phase 1	Terminated	EMD Serono

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Otsuka's Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy, Intensifying Competition with Vera Therapeutics

22 days ago

Otsuka's experimental therapy sibeprenlimab demonstrated a 51.2% reduction in proteinuria levels in patients with IgA Nephropathy at nine months in a late-stage trial.

Vera Therapeutics Secures $500 Million Credit Facility to Support Atacicept Commercial Launch

25 days ago

Vera Therapeutics has secured a new $500 million credit facility with Oxford Finance, replacing its existing $50 million facility and reducing borrowing costs by 320 basis points.

Vera Therapeutics' Atacicept Achieves 46% Protein Reduction in Phase 3 IgA Nephropathy Trial

a month ago

Vera Therapeutics' atacicept demonstrated a statistically significant 46% reduction in proteinuria in patients with IgA nephropathy, exceeding the 35% reduction seen in Phase 2 trials.

IgA Nephropathy Pipeline Shows Robust Growth with 30+ Therapies in Development

2 months ago

DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape.

Wolfe Research Initiates Coverage on Vera Therapeutics with Bullish Outlook on IgA Nephropathy Treatment

5 months ago

Wolfe Research has initiated coverage of Vera Therapeutics with an Outperform rating and a $49 price target, expressing optimism ahead of Phase 3 Origin trial results expected in Q2.

AI-Powered Research

Premium Access

Overview

Background

Indication

Associated Conditions